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Abstract Background and aims: Obesity is often associated with an increased cardiovascular risk. The food industry and the associated research activities 
focus on formulating products that are a perfect mix between an adequate fat content and health. We evaluated whether a diet enriched with Bio-Oil Spread 
(SD), an olive oil-based innovative food, is cardioprotective in the presence of high-fat diet (HFD)-dependent obesity.Methods and Results: Rats were fed 
for 16 weeks with normolipidic diet (ND; fat: 6.2%), HFD (fat: 42%), and ND enriched with SD (6.2% of fat þ 35.8% of SD). Metabolic and 
anthropometric parameters were measured. Heart and liver structures were analyzed by histochemical examination. Ischemic susceptibility was evaluated 
on isolated and Langendorff-perfused cardiac preparations. Signaling was assessed by Western blotting. Compared to ND rats, HFD rats showed increased 
body weight and abdominal obesity, dyslipidemia, and impaired glucose tolerance. Morphological analyses showed that HFD is associated with heart and 
liver modifications (hypertrophy and steatosis, respectively), lesser evident in the SD group, together with metabolic and anthropometric alterations. In 
particular, IGF-1R immunodetection revealed a reduction of hypertrophy in SD heart sections. Notably, SD diet significantly reduced myocardial 
susceptibility against ischemia/reperfusion (I/R) with respect to HFD through the activation of survival signals (Akt, ERK1/2, and Bcl2). Systolic and 
diastolic performance was preserved in the SD group. Conclusions: We suggest that SD may contribute to the prevention of metabolic disorders and 
cardiovascular alterations typical of severe obesity induced by an HFD, including the increased ischemic susceptibility of the myocardium. Our results 
pave the way to evaluate the introduction of SD in human alimentary guidelines as a strategy to reduce saturated fat intake.  
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Introduction 
Men and women of all ages, races, and ethnic groups can be affected by obesity [1] and this is often accompanied by an increased 
morbidity and mortality due an increase of cardiovascular disease (CVD) risk factors [2,3]. Severe obesity causes permanent 
hemodynamic alterations that progressively impair cardiac structure and function. When comorbidities (i.e., systemic hypertension, sleep 
apnea, and hypoventilation) are present together with obesity, cardiac alterations progress to heart failure (HF) [4]. Metabolic syndrome 
(MetS) is a condition in which a high CVD risk is associated with obesity. It is characterized by disturbed glucose homeostasis, 
dyslipidemia, and hypertension [5] and is established in the presence of three of the following parameters: (i) waist circumference >40 
(men) and >35 (women) inches; (ii) triglycerides >150 mg/dl; (iii) HDL (high-density lipoprotein) cholesterol <40 (men) and <50 
(women) mg/dl; (iv) blood pressure >130/85 mm Hg; and (v) fasting glucose >100 mg/dl [6]. Currently, nutritional therapy is regarded 
as the best practice to prevent and/or reduce the cardiovascular damages associated with MetS [7]. 
According to the “lipid hypothesis,” [8] a high intake of saturated fatty acids (SFAs) severely affects cardiovascular health. On the 
contrary, dietary polyunsaturated fatty acids (PUFAs) and monounsaturated fatty acids (MUFAs) reduce cardiovascular morbidity and 
mortality in the presence of MetS [9]. In this regard, it is known that olive oil, largely present in Mediterranean diet, improves 
postprandial lipoprotein metabolism [10], reduces blood pressure in both normal and hypertensive subjects, and improves carbohydrate 
metabolism in healthy and type 2 diabetic subjects [11]. 
Therefore, food industry and the associated research activities focus on the formulation of alimentary products that perfectly 
combine adequate lipid contents and cardiovascular health. Bio-Oil Spread is an innovative food mainly based on olive oil. The food 
industry can use this hard fat phase as margarine, a shortening, or butter replacer for baker production, and/or as a ready-to-eat fat spread. 
Rheologically, it is a structured water-in-oil emulsion. The increased consistency of olive oil is not achieved by common techniques 
such as catalytic hydrogenation, transesterification, or chemical recombination of the starting oil, but is obtained by a novel technique, 
named organogelation [12]. Organo gels are gels based on an organic solvent (a vegetable oil) which reaches a solid-like consistency due 
to the self-assembly of “low molecular weight organogelator molecules” into a three-dimensional structure. This structure in turn entraps 
the solvent that, in the case of Bio-Oil Spread, is represented by the water droplets of the emulsion [13]. Therefore, the structured oil 
phase, that is, the organogel, produces a very consistent fat that, if necessary, can be emulsified for producing a spreadable material. This 
occurs without chemical changes in the inner structure of triglycerides, but by physical interactions between organogelator molecules; 
these molecules begin to crystallize at high temperatures and create a network at room temperature Based on these premises, we aimed to 
investigate whether and to which extent, compared with a standardized high-fat diet (HFD) used to induce MetS, a diet enriched with Bio-
Oil Spread influences the rat metabolic and “anthropometric” parameters, associates with cardiac and hepatic structural changes, and 
influences myocardial ischemic susceptibility induced by ischemia/reperfusion (I/R) and post-conditioning (post-C) maneuvers. 
We found that, with respect to rats fed with HFD, those fed with Bio-Oil Spread show a limited lipid accumulation, a reduction of body 
weight and abdominal circumference, and a lower ischemic susceptibility, revealed by a smaller infarct area and by a better postischemic 
recovery associated with pro-survival molecular cascade activation. Our results are of interest as they may open new perspectives 
in the use of innovative alimentary products able to contribute to prevent and/or treat HFD-dependent metabolic disorders and 
cardiovascular dysfunctions. 
 
Methods 
Animals 
The study was performed on Sprague Dawley rats. The initial weights of rats fed with normolipidic diet (ND), HFD, and SD (Bio-Oil 
Spread diet) are, respectively, 357 _ 7, 359 _ 6, and 358 _ 5 g. Animals were housed one per cage, kept under controlled light and 
temperature conditions, and fed by free access to a normal chow diet and water. The scientific project was supervised and approved by the 
local ethical committee, and the experimental protocols were carried out according to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institute of Health (publication No. 85e23, revised 1996) and to the Italian law (DL 116/92 and 
DL 26/14). 
Drugs and chemicals 
Bio-Oil Spread 
Bio-Oil Spread is a water-in-oil emulsion based on an oil phase mainly comprising extra-virgin olive oil (Gabro, Italy) for more than 
60%w/w, cocoa butter (Icam, Italy), and Myverol (50% of glyceryl monostearate and 50% glyceryl monopalmitate, Kerry Group, 
Ireland). Distilled water is the aqueous phase of the final emulsion. Oil phase is produced by heating olive oil and mixing cocoa butter and 
monoglycerides; finally, emulsification is carried out at low temperatures with water. Further details can be found in the patent WO 
2013111058 A1 by De Cindio et al. [14]. 
HFD, ND, and SD formula 
Teklad diet TD.88137 purchased by Harlan (Udine, Italy) is a hypercaloric diet used as HFD (42% kcal fat, 15.2% kcal protein, and 
42.7% kcal carbohydrate). On the contrary, Diet 2018 (Harlan, Italy; 6.2% kcal fat, 18.6% kcal protein, and 44.2% kcal carbohydrate) was 
used as ND. ND was enriched with SD, an olive oil emulsion, to obtain a fat percentage similar to that of HFD (35.8% kcal SD); SD was 
stored at 4 _C to avoid auto-oxidation of the fatty components. The anthropometric analysis of each rat, subjected to the diet, was checked 
weekly to evaluate the development of obesity [15,16]. 
Experimental protocols 
Rats were divided into five groups (n Z 20 for each group) and fed as follows: 
_ Group ND (fed with ND; n Z 20); 
_ Group HFD (fed with HFD; n Z 20); 
_ Group SD (fed with ND enriched with SD; n Z 20); 
_ Group NDM1 (fed with ND enriched with 30 g/kg Myverol; n Z 5); 
_ Group NDM2 (fed with ND enriched with 60 g/kg Myverol; n Z 5); 
All the experimental groups were subjected to the diet for 16 weeks. At the end of treatment, all animals were subjected to the 
measurement of anthropometric parameters and plasma analysis. From the ND, HFD, and SD groups, 10 animals were assigned to I/R 
protocols, while 10 were randomly used for several immunohistochemistry and Western Blot analyses. NDM1 and NDM2 animals 
were assigned only to I/R protocols. 
Anthropometric variables 
Body weight, abdominal circumference, and length of each rat were measured weekly. The total amount of food and water consumed was 
recorded every day. The rat length was evaluated by measuring the noseeanus distance [17]. Body mass index (BMI) was calculated as 
reported by Panchal SK et al. [18] After the sacrifice, the abdominal fat tissue was removed and separately weighed. 
Plasma analysis 
Blood samples were collected both weekly and before the sacrifice, through the tail vein; the amount of blood was <1% of the body 
weight (e.g., 1 mL from a 250-g adult rat). Blood plasma was separated by centrifugation for 15 min at 1000 _ g at 2e8 _C within 30 min 
of collection. A plasma aliquot was refrigerated at 4 _C for glucose analysis, while the remaining plasma was frozen (_80 _C) for the 
subsequent biochemical analyses. The glucose levels were determined using a Glucometer (ACCUCHEK, Roche Diagnostics, Germany). 
Total cholesterol, HDL cholesterol, LDL cholesterol, and insulin levels were evaluated by commercial assay kits (enzyme-linked 
immunoassay, ELISA). The kit used for the determination of total cholesterol, HDL cholesterol, and LDL cholesterol levels is PKL_ 
POKLER ITALY S.r.l. The kit used for the determination of insulin levels is Millipore (St. Charles, MO, USA). 
Calculation of insulin sensitivity index (HOMA-IR) 
The measurement of basal insulin sensitivity, an index of insulin resistance (HOMA-IR; homeostatic model assessment-estimated insulin 
resistance), was performed as reported by Matthews et al. [19] Assuming that the control young adult rats have an average HOMA-IR of 
1, analogous to the assumptions applied in the development of HOMA-IR in humans, this index was calculated as the product of the 
fasting plasma glucose (FPG) and fasting plasma insulin (FPI) levels, divided by a constant [20]. The equation is HOMA-IR Z 
(FPG(mUI/ml) _ FPI(mg/dl))/2.430. 
Cardiovascular structure and function After 16 weeks of diet, the rats were anesthetized by ethyl carbamate (2 g/kg body weight, 
intraperitoneal) and were sacrificed, and the heart was assigned to the specific 
protocol. 
Light microscopy 
After sacrifice, hearts (n Z 4 for each group), removed from the pericardial cavity and flushed with phosphate buffered  
saline (PBS; pH: 7.6), were blocked in diastole with an excess of KCl (0.5 g/L). The liver was collected from the same animal (n Z 3 for 
each group) and dissected into several sections. Both heart and liver were treated as follows: tissues were fixed in MAW fixative 
(methanoleacetoneewater, 2:2:1), dehydrated in graded ethanol, embedded in paraplast (Sherwood, St. Louis, MO, USA), and serially 
sectioned at 8 mm. Sections were placed onto Superfrost Plus slides (Menzel-Gläser, Braunschweig, Germany). The sections were stained 
either with hematoxylin and eosin for a general assessment of tissue structure, or with Sirius red for collagen fiber detection. 
Immunohistochemistry 
In parallel with the evaluation of the localization pattern of the IGF-1R (insulin-like growth factor-1 receptor), deparaffinized and 
rehydrated heart sections were processed by immunohistochemical stain using an HRP/DAB (3, 3-diaminobenzidine) detection kit 
(Abcam, Cambridge, MA, USA). Briefly, the sections in PBS were pretreated with H2O2 to remove endogenous peroxidase activity, and 
then incubated for 1 h with Protein Block and overnight with mouse polyclonal IGF receptor antibody (1:100) at 4 _C. The slides were 
than washed in PBS and incubated with biotinylated goat anti-mouse IgG (immunoglobulin G) and finally with streptavidineperoxidase 
complex. The signal was visualized using diaminobenzidine (DAB) as the final chromogen. The sections were observed using a ZEISS 
AXIOSKOP microscope and the images were digitalized by Axiocam 105 color, ZEISS. 
Cardiac function 
Cardiac function was evaluated with the Langendorff method. After sacrifice, the heart was rapidly excised, placed in ice-cold perfusion 
buffer, cannulated through the aorta, and perfused at constant retrograde flow (12 ml/ min) and constant temperature (37 _C). The 
perfusion medium used was a modified KrebseHenseleit solution (KHs; pH 7.4) gassed with 95% O2 and 5% CO2 containing (in mmol/l) 
113.0 NaCl, 4.7 KCl, 1.2 MgSO4, 25.0 NaHCO3, 1.2 KH2PO4, 1.8 CaCl2, 11.0 glucose, 1.1 mannitol, and Naepyruvate 5 [21]. The left 
ventricular pressure (LVP) was measured through a latex water-filled balloon inserted into the left ventricle through the mitral valve, 
connected to a pressure transducer (BLPR gauge, WRI, Inc. USA), and set to obtain a left ventricular end-diastolic pressure (LVEDP) of 
5e8 mm Hg [21]. 
Ischemia/reperfusion (I/R) and ischemic postconditioning (Post-C) After 40 min of stabilization, the baseline parameters were recorded 
and each heart was randomly assigned to one of the experimental groups described below. 
1) ND I/R group (n Z 10): after 30 min of global noflow ischemia, hearts were subjected to 120 min of reperfusion; 
2) HFD I/R group (n Z 10): after 30 min of global noflow ischemia, n Z 5 hearts were subjected to 120 min of reperfusion, while n Z 5 
hearts were subjected to five cycles of 10 s of reperfusion and 10 s of ischemia and then to 120 min of reperfusion [22]; 
3) SD I/R group (n Z 10): after 30 min of global no-flow ischemia, n Z 5 hearts were subjected to 120 min of reperfusion, while n Z 5 
hearts were subjected to five cycles of 10 s of reperfusion and 10 s of ischemia and then to 120 min of reperfusion [22]; 
4) Myverol (30 mg/kg) group (n Z 5): hearts were stabilized and subjected to 120 min of perfusion; 
5) Myverol (60 mg/kg) group (n Z 5): hearts were stabilized and subjected to 120 min of perfusion. 
Cardiac performance before and after ischemia was evaluated by analyzing LVP, as an index of the recovery in contractile activity, and 
LVEDP as an index of contracture (i.e., myocardial tissue damage), defined as an increase in LVEDP of 4 mm Hg above the baseline 
level [23]. 
Assessment of myocardial injury 
In order to assess infarct area extension, after each experimental protocol, hearts were rapidly removed from the perfusion apparatus and 
the left ventricles were dissected into 2- to 3-mm circumferential sections. After incubation at 37 _C for 20 min in a phosphate buffer plus 
0.1% of nitro blue tetrazolium, unstained necrotic tissue was carefully separated from the stained tissue and weighed. The infarct size was 
expressed as a percentage of the total left ventricular mass, including septum [23]. 
Western blotting 
Hearts (n Z 3 for each group) were immediately frozen in liquid nitrogen at the end of I/R protocols and stored at _80 _C until their 
homogenization in RIPA (radioimmunoprecipitation assay) buffer. Equal amounts of total protein (40e100 mg), for each sample, were 
loaded on an 8e12% sodium dodecyl sulfate (SDS)epolyacrylamide gel and then transferred to a PVDF (polyvinylidene difluoride) 
membrane. Blots were blocked for 1 h by a 5% nonfat milk solution and then incubated overnight at 4 _C with primary antibodies (diluted 
1:1000) recognizing pAKT, p-ERK1/2, Bcl2, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase; all antibodies were purchased 
from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes were subsequently incubated for 1 h at room temperature with 
horseradish peroxidase (HRP)-conjugated secondary antibodies rabbit anti-mouse (1:10.000) or goat anti-rabbit (1:10.000; Stressgen, 
Victoria, BC, Canada). GAPDH was used as the loading control. The level of proteins and phosphoproteins was detected using an ECL_ 
(Enhanced chemiluminescence) System (GE Healthcare, Milan, Italy). Autoradiographs were obtained by exposure to X-ray films, 
immunoblots were digitalized, and the densitometric analysis of the bands was carried out using NIH IMAGE 1.6 for a Macintosh 
computer based on 256 gray values (0 Z white; 256 Z black). 
Lactate dehydrogenase 
Lactate dehydrogenase (LDH) release, which is known to be reduced by post-C [22], was evaluated in coronary effluent in each 
experimental group. Perfusate samples were collected during the reperfusion through a catheter inserted into the right ventricle via the 
pulmonary artery. LDH concentration was measured by kit for rat LDH ELISA assay (E02L0006 Blue Gene). The data were expressed as 
cumulative values for the entire reperfusion period. 
Statistics 
Statistical analysis was performed by using the GraphPad Prism Software_ (version 5.0; Graph Pad Software, San Diego, CA, USA). Data 
were expressed as the mean _ SEM (standard error of mean). One-way ANOVA (analysis of variance) test and nonparametric 
KruskaleWallis test followed by Dunn’s multiple comparison test (for post-ANOVA comparisons) were used when appropriate. 
Statistically significant differences: p < 0.05. 
Results 
Anthropometric variables 
As shown in Table 1, with respect to ND-fed animals, rats fed for 16 weeks with HFD showed a significant increase in BMI, waist 
circumference, abdominal fat, and food intake (*p < 0.05). A decrease in all the above parameters was observed in SD animals. Notably, 
with respect to the HFD group, SD rats showed a significant decrease in abdominal fat and food intake (xp < 0.05). All groups showed 
similar water intake. 
 
 
 
Metabolic variables 
Rats fed with HFD for 16 weeks showed a higher blood glucose level than ND, thus suggesting a diet-dependent glucose intolerance in 
HFD ()p < 0.05). In the SD group, the blood glucose level was significantly lower with respect to HFD and higher than that detected in 
the ND group (_, xp < 0.05). In addition, the total cholesterol level was significantly higher in HFD than in SD rats (p < 0.05), but it was 
significantly lower in the ND group compared with the HFD and SD groups (_, xp < 0.05). Similar changes were also observed for HDL 
and LDL (see Table 2). HOMAIR, calculated as the product of fasting plasma glucose and fasting plasma insulin levels, assuming that the 
ND group has an index of 1.0, was 2.60 in the HFD group, while it was 1.31 in the SD group. 
Morphological experiments 
Heart 
The sections of the left ventricle from rats fed with HFD showed a higher infiltration of inflammatory cells(Fig. 1D) and collagen 
deposition (Fig. 1) compared to the ND rats (Fig. 1A, B, and C). These changes were attenuated in the left ventricle of the rats fed with 
SD with respect to the HFD group (Fig. 1G, H, and I). The analysis of the ventricular structure revealed a higher percentage of 
myocardium per unit of area in the HFD-fed rats (86.23%), while the percentage in the SD group was similar to that measured in the ND 
group (77.9% and 80.51%, respectively). Immunohistochemical analysis, using anti-IGF-1 receptor antibody as a marker of hypertrophy, 
revealed a major expression of this molecule in HFD with respect to ND heart, suggesting a higher degree of myocardial hypertrophy. On 
the contrary, the IGF-1R expression in SD heart was reduced with respect to HFD heart and was similar to ND heart (Fig. 2). 
Liver 
The liver from HFD rats showed a higher infiltration of inflammatory cells (Fig. 3A and B) along with the presence of fat vacuoles (Fig. 
3B) and portal fibrosis (Fig. 3E), which were of a lesser extent in liver from ND (Fig. 3A and D) and, in particular, in liver from SD rats 
(Fig. 3C and F). 
Cardiovascular function 
Basal cardiac parameters 
Cardiac parameters, obtained after 20-min equilibration, are given in Table 3. Endurance and stability of the preparations 
for each heart, analyzed by measuring the performance variables every 10 min, was stable up to 180 min. Under basal conditions, a 
significant increase in CP (circulatory power) was observed in HFD with respect to ND ()p < 0.05). In addition, rats fed with HFD diet 
showed a significant increase in heart weight with respect to the SD and ND groups (), _, xp < 0.05). 
Postischemic cardiac function 
Systolic function is represented by the value of developed LVP recovery (dLVP; i.e., inotropic activity). As shown in Fig. 4A, in the 
postischemic phase, at the end of the reperfusion, HFD post-C dLVP was significantly higher than HFD (xp < 0.05). Notably, in SD and 
SD post-C, the systolic recovery is higher than in HFD and ND (xp < 0.05). LVEDP (i.e., contracture state) represents the diastolic 
function in the postischemic phase. In the ND and HFD groups, LVEDP values indicate the presence of contracture. On the contrary, in 
HFD post-C, the SD and SD post-C LVEDP values were lower when compared to their respective ND counterpart (xp < 0.05; Fig. 4B). 
Infarct size (IS) 
Infarct area was similar in ND and HFD hearts (w67% of risk area; Fig. 5A). In HFD post-C, IS was significantly lower (w55% of risk 
area) compared to HFD and ND hearts(xp < 0.05). Of note, in SD and SD post-C, IS was reduced atw48% and w42% of risk area, 
respectively (xp < 0.05). In all groups, the cardioprotective profile of LDH release was similar to IS (Fig. 5B). 
Myverol group 
In order to exclude the possible influence of the additive Myverol on rat anthropometric and metabolic parameters and on cardiac 
performance, two groups were fed with ND enriched with Myverol at lower (30 gr/kg of diet, i.e., 2% of Myverol) and higher (60 gr/kg of 
diet, i.e. 5% of Myverol) concentrations. The systolic and diastolic functions and IS and LDH levels in these groups are similar to those in 
the ND group (data not shown). 
Involvement of RISK pathway 
In heart homogenates from all groups, the expression of the phosphorylated kinases ERK1/2 and AKT was evaluated. Densitometric 
analysis of the WB bands (Fig. 6) showed that the expression of p-AKT was higher in the SD and SD post-C groups ()p < 0.05) than in 
the HFD, HFD post-C, and ND groups. ERK1/2 phosphorylation was higher in the HFD post-C, SD, and SD post-C groups ()p < 0.05) 
than in the HFD and ND groups. 
Involvement of anti-apoptotic protein 
Western blotting experiments in ND, HFD, HFD post-C, SD, and SD post-C hearts showed that the levels of the antiapoptotic protein 
Bcl2 were significantly increased in HFD post-C, SD, and SD post-C hearts groups, with respect to the HFD and ND groups ()p < 0.05; 
Fig. 7). 
 
Discussion 
Proper nutrition is a major determinant for prevention and treatment of many diseases. This becomes even more important in the presence 
of obesity, a severe problem in the Western society, often associated with fatal diseases [24]. Although genetic factors may increase the 
propensity to obesity, epidemiological evidence identified a strong correlation with a diet rich in fat [25], which is often associated with a 
significant increase in CV risk [26]. In this regard, the industrial research on nutrition is constantly attempting to formulate innovative 
products that are a perfect balance between fat content and health. Bio-Oil Spread, containing olive oil as the main ingredient, is a 
recently developed innovative alimentary material. The present work is the first to analyze the longterm metabolic and cardiac effects 
induced by the dietary supplementation with Bio-Oil Spread on rats. The results showed that, with respect to animals fed with HFD, those 
fed with this novel product show changes in anthropometric and metabolic parameters. Their heart is preserved by obesity-dependent 
morpho-functional alterations and is protected against ischemic injury through the activation of pro-survival pathways such as RISK and 
SAFE and antiapoptotic proteins. We here observed that rats fed with a diet enriched with Bio-Oil Spread showed reduced anthropometric 
index, in particular abdominal fat, with respect to HFD-fed animals. As largely shown in animal models and in humans, these parameters 
are closely associated with dyslipidemia, disorders in glucose metabolism, and severe cardiovascular dysfunctions, which remarkably 
enhance the risk of myocardial infarction [27,35,36]. Consistent with these metabolic alterations, we found in HFD rats a lipid profile 
indicative of dyslipidemia. By contrast, SD animals showed an opposite behavior, as they were characterized by HDL values that were 
higher than those measured before the dietary treatment. At the same time, blood glucose and insulin levels, which were higher in HFD-
fed rats, were reduced in SD rats. Insulin resistance plays a role in the pathogenesis of diabetes and metabolic syndrome. Accordingly, it 
is important to determine, in vivo, the insulin sensitivity, both in human and in animal models [28]. In human studies, a number of simple 
indexes, derived from fasting glucose and insulin levels, have been obtained and validated, for example, HOMA-IR index. An increased 
HOMA-IR index was suggested to be indicative of insulin resistance typically in the early stages of diabetes or steatohepatitis [29]. Based 
on these premises, in the present study, we adapted this index to the rat, a widely used model to study insulin resistance. HOMA-IR index 
was used on the basis of biochemical parameters (glucose and insulin) that can be obtained in a single sample of fasting blood. Our data 
showed that HOMA-IR in the SD group is reduced with respect to the HFD group, thereby suggesting that the Spread Bio Oil diet did not 
determine insulin resistance. High blood glucose and insulin levels are typical traits of obesity and are responsible for glucotoxicity [30]. 
This determines cardiac injury through direct and indirect effects on cardiac myocytes, fibroblasts, endothelial cells, via overproduction of 
reactive oxygen species, and apoptosis [30]. Hyperglycemia also contributes to alteration of cardiac structure and function through 
advanced glycation end products and posttranslational modification of extracellular matrix proteins, leading to an altered 
expression/function of intramyocellular calcium channels. These processes contribute to systolic and diastolic cardiac dysfunction 
[31,32]. In obesity, the cardiovascular condition is aggravated by the detrimental role of the excessive adipose tissue and fat-free mass, 
which results in a higher metabolic demand.  This leads to hyperdynamic circulation, increased blood volume, and cardiac output [33]. 
Heart weight and body weight exhibit a linear relationship; peripheral resistances increase, which enhance left ventricular afterload [34]. 
In long-standing obesity, these changes are associated with left ventricular hypertrophy [35]. Interestingly, we found that rats fed with 
Bio-Oil Spread showed a heart weight similar to that of ND animals. This is opposite to the observations in HFD rats. Moreover, the 
cardiac tissue was characterized by a scarce infiltration of inflammatory cells, the absence of ventricular hypertrophy, and a limited 
collagen deposition, indicative of a reduced ventricular stiffness. In addition, IGF1R, an established factor in cardiac hypertrophy, is 
overexpressed in hypertrophic heart mediating the hypertrophic pathology process. In particular, it has been shown that the short-term 
activation of IGF signaling pathway promotes physiologic growth, whereas sustained hyperactivation leads to the development of 
pathologic hypertrophy and HF [36,37]. Interestingly, we observed that the expression of IGF-1R and myocardial hypertrophy in SD 
heart, are lower than those of HDF heart, suggesting that SD diet protects the heart from obesity dependent hypertrophy. These 
observations are of interest as they may necessitate a preserved heart performance in the presence of a diet enriched with Bio-Oil Spread. 
Of note, we observed in SD rats that, although body weight increased, abdominal fat decreased. Together with the ameliorated metabolic 
profile, this is indicative of a reduced risk of myocardial infarction, as suggested by the direct relationship described between abdominal 
obesity and the increased myocardial risk [38e40]. Consistent with this, the heart of rat fed with Bio-Oil Spread showed a higher 
protection against I/R injury with respect to HFD animals in the presence of ischemic Post-C maneuvers. This was indicated by a 
significant reduction of IS and LDH release and by a marked improvement of the postischemic contractile function expressed as an 
increase in LVP and a decrease of contracture development. It is known that cardiac protection is mediated by the activation of the pro-
survival RISK pathway [41]. This cascade involves PI3K/Akt, PKCε, and ERK1/2, which require the opening of mitoKATP channels 
[42e44]. Here we observed that, compared to HFD-fed rats, cardioprotection induced by SD diet increased the expression of p-Akt and p-
ERK. This agrees with the involvement of these kinases in ischemic pharmacological cardioprotection and Post-C maneuvers [45,46]. In 
line with an SD-associated protective role, the heart of SD-fed rats showed an increased expression 
of the anti-apoptotic protein Bcl-2 which correlates 
with the reduction of IS. 
Human application 
In the last years, food industry is focusing on formulating healthy products for consumers, also forced by new legislative requirements. 
This is encouraging research for increasing quality and wholesomeness of food materials. Bio-Oil Spread is a healthy alternative to 
conventional margarines or shortenings. For instance, margarines can be used as a ready-to-eat product (fat spread) or as ingredients for 
leavened and baked foodstuffs. Independent of the intended use, their production process always involves different steps aimed at 
producing W/O emulsions. The specific rheological characteristics (hard gel-like properties) are given by the saturated fats of the oil 
phase, which form an interacting network surrounding water droplets [47]. Oil-phase structuring is achieved through two alternative 
methods. The first is the addition of natural hard fats (saturated fats), mainly palm oil derivatives, to the oil phase. However, at present, 
intensive use of palm oil in the food industry is discouraged because of problems associated not only with rainforest destruction but also 
with the high palmitic acid content, considered responsible for the hypercholesterolemic effect [48]. The second alternative is the partial 
hydrogenation of vegetable oils [49] with a catalytic three-phase process [50] to saturate carbonecarbon double bonds. This implies that 
the movement of double bonds in their positions on the fatty acid carbon chain, producing isomers and trans-fatty acids (TFAs) has 
several negative effects on consumers’ health [51,52]. Based on these premises, Bio-Oil Spread could be addressed to human nutrition 
because it is characterized by rheological properties very similar to those of spreads or margarines, for which it could be considered a 
substituent. However, the oil phase is structured by organogelation, and therefore, without chemical recombination  of the molecules 
within raw materials. Bio-Oil Spread composition also includes cocoa butter in its formulation.  
Therefore, its lipid profile contains stearic acid (principally present in cocoa butter) and high-oleic acid oils (i.e. olive oil). This is very 
intriguing because of the neutral effects of stearic acid on cholesterol levels and the beneficial effects of oleic acid on human health [52]. 
Strengths and limitations of the study  
This study is the first to highlight the benefits of the dietary consumption of Bio-Oil Spread, a novel olive oil-based food. It also provides 
indications concerning the impact of this alimentary product on health, comparing its effects with those of the classic hyperlipidic diet. 
The use of an animal model represents a limitation as it reveals aspects that cannot be directly used for applicative purposes and require 
further efforts to be translated into the human setting. At the same time, this is an advantage as it allows the study of aspects of the 
complex networks of physiological and pathological processes that are activated in the presence of obesity. Animal studies represent, 
even today, a fundamental preclinical step to investigate, at the organ and molecular level, the mechanisms related to the onset and 
progression of diseases. In this regard, the results provided  by the present study represent a stimulating scientific base for further 
investigations focused on the clarification of the applicative potential of Bio-Oil Spread in human nutrition with the purpose to reduce the 
negative impact of a high lipid diet on cardiovascular health. 
Conclusion 
This study provides first evidence that long-term dietary supplementation with the innovative alimentary product, Bio-Oil Spread, may 
contribute to prevent metabolic disorders and cardiovascular alterations typical of severe obesity induced by an HFD, including the 
increased ischemic susceptibility of the myocardium. Our results enrich the knowledge on the beneficial effects of olive oil on the 
cardiovascular health and pave the way to evaluate the introduction of Bio-Oil Spread in human alimentary guidelines as a strategy to 
reduce saturated fat intake. 
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Figure 1 Inflammation (D) and fibrosis (C, F, I) in the heart from ND (A, B, C), HFD (D, E, F), and SD (G, H, I) rats (n Z 4 for each group). Hematoxylineeosin 
staining (A, B, D, E, G, and H) of LV showed infiltration of inflammatory cells in HFD rats (D black arrows). Hypertrophied cardiomyocytes 
are evident in HFD (E) respect to ND (B) and SD (H) rats. Picrosirius red staining of LV (C, F, and I) showed collagen deposition (blue 
arrows). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)  
 
 
Figure 2 Immunohistochemical localization of the IGF 1R in the ventricular cardiomyocytes (black arrows) and vascular endothelium (red arrows) 
of ND (A), HFD (B), and SD (C) rats. A higher signal was detected in HFD (B) with respect to ND (A) and SD (C) heart sections. (For interpretation of the 
references to color in this figure legend, the reader is referred to the web version of this article.) 
 
 
Figure 3 Inflammation (black arrows), fat deposition (gray arrows), and fibrosis (blue arrows) in the liver from ND (A, D), HFD (B, E), SD (C, F) rats. 
Hematoxylin and eosin staining (A, B, C) of the liver showed inflammatory cells and enlarged fat vacuoles in HFD rats. Picrosirius red staining (D, E, F) 
showed collagen deposition in the hepatic portal region. (For interpretation of the references to color in this figure legend, the reader is referred to 
the web version of this article.) 
 
 
Figure 4 (A) Systolic function. Variation of developed LVP (dLVP) in ND (n Z 10), HFD and HFD post-C (n Z 10), SD, and SD post-C groups (n Z 10). Data are 
presented in mm Hg at the end of 120-min reperfusion with respect to baseline level of 10 experiments for each group. (B) Diastolic function. Left ventricular end-
diastolic pressure (LVEDP): data are expressed in mm Hg at the end of 120-min reperfusion. Significance of difference (one-way ANOVA) from control values of 
each group versus ND: x Z p < 0.05. 
 
 
Figure 5 (A) Infarct size. The amount of necrotic tissue measured after 30-min global ischemia and 120-min reperfusion is expressed as percent of the left ventricle 
(% IS/LV) in ND (n Z 10), HFD, and HFD post-C (n Z 10), SD, and SD post-C groups (n Z 10). (B) LDH release. Values are expressed as means _ SEM of absolute 
data (ng/ml) in ND, HFD, HFD Post-C, SD, and SD post-C groups. Significance of difference (one-way ANOVA) from control values of each group versus ND: x Z 
p < 0.05.  
 
Figure 6 Representative Western blots and relative densitometric analysis of (A) AKT and (B) ERK1/2 phosphorylation in ND, HFD, HFD post-C, SD, 
and SD post-C groups. Percentage changes were evaluated as means _ SEM of three experiments for each group. Significance of difference (one-way 
ANOVA) from control values of each group versus ND: )p < 0.05. 
 
Figure 7 Representative Western blots and relative densitometric analysis of Bcl2 phosphorylation in the ND, HFD, HFD post-C, SD, and SDpostC 
groups. The percentage changes were evaluated as means _ SEM of three experiments for each group. Significance of difference (one-way ANOVA) 
from control values of each group versus ND: )p < 0.05. 
